Sign In
Buy VTGN
$0.560
-0.0199 (-3.43%)
At Close: Jun 03, 2026
Novel Anxiety and Depression Approach by VistaGen Therapeutics
09:33am, Tuesday, 27'th Apr 2021
The COVID-19 pandemic has exacerbated mental health issues and is triggering new conditions for people already suffering from mental illnesses and substance abuse. Social anxiety disorder (SAD) is o
VistaGen: Phase 2 Success In Anxiety Disorder, Phase 3 To Begin
08:00am, Sunday, 25'th Apr 2021
VistaGen has had a tumultuous history, but recent trials have seen success. They may start phase 3 trials for PH94B in May.
VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March
07:46am, Tuesday, 16'th Mar 2021
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medici
VistaGen's PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study
08:30am, Thursday, 11'th Mar 2021
PH10 may have stand-alone potential to displace current oral antidepressants in the drug treatment paradigm for depression disorders PH10 may have stand-alone potential to displace current oral antide
VTGN Stock Price Increases Over 13% Pre-Market: Why It Happened
07:09am, Thursday, 18'th Feb 2021
The stock price of Vistagen Therapeutics Inc (NASDAQ: VTGN) has increased by over 13% pre-market as of 7:01 AM ET. This is why it happened.
Multiple clinical studies anticipated to launch in Calendar 2021, notably pivotal Phase 3 clinical studies of PH94B as a potential acute treatment of anxiety in adults with social anxiety disorder (SA
VistaGen: Patience Could Lead To Significant Upside
01:07am, Sunday, 24'th Jan 2021
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a generation of novel medicines for anxiety, depression, and other central nervous system disorders, pri
Dr. Louis Monti, VistaGen's Newly-Appointed Vice President, Translational Medicine, and Dr. Michael Liebowitz, VistaGen CNS Clinical and Regulatory Advisory Board Member, Collaborate on Review Dr. Lou
VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering
04:01pm, Tuesday, 22'nd Dec 2020
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN) (“VistaGen”), a biopharmaceutical company committed to developing a new generation of me
Why BioCryst, VistaGen And Teladoc Are Moving Today
12:23pm, Tuesday, 22'nd Dec 2020
VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher after Maxim raised its price target on the stock from $3 to $5. VistaGen Therapeutics is a biotechnology firm.
VistaGen Therapeutics Announces Pricing of Underwritten Public Offering
06:25am, Friday, 18'th Dec 2020
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potent
VistaGen Therapeutics Announces Proposed Underwritten Public Offering
04:01pm, Thursday, 17'th Dec 2020
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potent
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other centr
